JP2022518906A - サルカルディン塩 - Google Patents

サルカルディン塩 Download PDF

Info

Publication number
JP2022518906A
JP2022518906A JP2021542541A JP2021542541A JP2022518906A JP 2022518906 A JP2022518906 A JP 2022518906A JP 2021542541 A JP2021542541 A JP 2021542541A JP 2021542541 A JP2021542541 A JP 2021542541A JP 2022518906 A JP2022518906 A JP 2022518906A
Authority
JP
Japan
Prior art keywords
solid form
xrpd pattern
sarcardin
peaks
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542541A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020159959A5 (https=
JP2022518906A5 (https=
Inventor
ロマーノ，スザンヌ，ジェイ．
リース，ヘイリー，アン
ゴードン ベンソン，ジョセフ，エドワード
コリンズ，サラ
ティー． エリオット，ゲイリー
ギリングス，ミレイユ
グデノフ，ロバート
タイリー，カーティス
Original Assignee
フヤ バイオサイエンス インターナショナル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フヤ バイオサイエンス インターナショナル エルエルシー filed Critical フヤ バイオサイエンス インターナショナル エルエルシー
Publication of JP2022518906A publication Critical patent/JP2022518906A/ja
Publication of JPWO2020159959A5 publication Critical patent/JPWO2020159959A5/ja
Publication of JP2022518906A5 publication Critical patent/JP2022518906A5/ja
Priority to JP2023188791A priority Critical patent/JP2024039020A/ja
Priority to JP2025114666A priority patent/JP2025165933A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
JP2021542541A 2019-01-29 2020-01-28 サルカルディン塩 Pending JP2022518906A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023188791A JP2024039020A (ja) 2019-01-29 2023-11-02 サルカルディン塩
JP2025114666A JP2025165933A (ja) 2019-01-29 2025-07-07 サルカルディン塩

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962798467P 2019-01-29 2019-01-29
US62/798,467 2019-01-29
US202062959687P 2020-01-10 2020-01-10
US62/959,687 2020-01-10
PCT/US2020/015370 WO2020159959A1 (en) 2019-01-29 2020-01-28 Sulcardine salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023188791A Division JP2024039020A (ja) 2019-01-29 2023-11-02 サルカルディン塩

Publications (3)

Publication Number Publication Date
JP2022518906A true JP2022518906A (ja) 2022-03-17
JPWO2020159959A5 JPWO2020159959A5 (https=) 2022-10-31
JP2022518906A5 JP2022518906A5 (https=) 2022-10-31

Family

ID=69724142

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021542541A Pending JP2022518906A (ja) 2019-01-29 2020-01-28 サルカルディン塩
JP2023188791A Pending JP2024039020A (ja) 2019-01-29 2023-11-02 サルカルディン塩
JP2025114666A Pending JP2025165933A (ja) 2019-01-29 2025-07-07 サルカルディン塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023188791A Pending JP2024039020A (ja) 2019-01-29 2023-11-02 サルカルディン塩
JP2025114666A Pending JP2025165933A (ja) 2019-01-29 2025-07-07 サルカルディン塩

Country Status (16)

Country Link
US (3) US11426382B2 (https=)
EP (1) EP3917921A1 (https=)
JP (3) JP2022518906A (https=)
KR (2) KR102405199B1 (https=)
CN (2) CN115385871A (https=)
AU (1) AU2020216925B2 (https=)
BR (1) BR112021014640A8 (https=)
CA (1) CA3128152A1 (https=)
CL (1) CL2021001968A1 (https=)
CO (1) CO2021011042A2 (https=)
IL (1) IL285184B2 (https=)
MX (2) MX2021009033A (https=)
PH (1) PH12021551818A1 (https=)
SG (1) SG11202108160YA (https=)
WO (1) WO2020159959A1 (https=)
ZA (2) ZA202105344B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529196A (ja) * 2020-06-12 2023-07-07 フヤバイオ インターナショナル，エルエルシー 急性心房細動の治療のためのサルカルディン投与
JP2024039020A (ja) * 2019-01-29 2024-03-21 フヤバイオ インターナショナル，エルエルシー サルカルディン塩

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364223B2 (en) 2018-12-13 2022-06-21 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511473A (ja) * 2009-11-17 2013-04-04 フヤ バイオサイエンス インターナショナル エルエルシー 心房細動の治療
JP2013511472A (ja) * 2009-11-17 2013-04-04 フヤ バイオサイエンス インターナショナル エルエルシー サルカルディン及びその塩の緩速点滴
JP2018506562A (ja) * 2015-02-26 2018-03-08 ジェネンテック， インコーポレイテッド ピロロピリジン化合物の結晶形態
WO2018156895A1 (en) * 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1299813C (zh) 2004-12-28 2007-02-14 华南理工大学 自动撕膜落料及多样性搅拌的机构和控制装置
CN1939298A (zh) * 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
CA3254279A1 (en) 2015-06-03 2025-03-18 Triastek, Inc. PHARMACEUTICAL FORMS AND RELATED USES
CA3023278C (en) 2016-05-05 2019-04-30 Triastek, Inc. Controlled release dosage form
KR20190107712A (ko) 2017-01-26 2019-09-20 트리아스텍 인코포레이티드 특정 위장 부위에서의 제어 방출의 투여 형태
US11364223B2 (en) 2018-12-13 2022-06-21 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
CN115385871A (zh) 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511473A (ja) * 2009-11-17 2013-04-04 フヤ バイオサイエンス インターナショナル エルエルシー 心房細動の治療
JP2013511472A (ja) * 2009-11-17 2013-04-04 フヤ バイオサイエンス インターナショナル エルエルシー サルカルディン及びその塩の緩速点滴
JP2018506562A (ja) * 2015-02-26 2018-03-08 ジェネンテック， インコーポレイテッド ピロロピリジン化合物の結晶形態
WO2018156895A1 (en) * 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024039020A (ja) * 2019-01-29 2024-03-21 フヤバイオ インターナショナル，エルエルシー サルカルディン塩
JP2023529196A (ja) * 2020-06-12 2023-07-07 フヤバイオ インターナショナル，エルエルシー 急性心房細動の治療のためのサルカルディン投与

Also Published As

Publication number Publication date
BR112021014640A8 (pt) 2022-12-20
US20200316024A1 (en) 2020-10-08
PH12021551818A1 (en) 2022-03-28
KR102405199B1 (ko) 2022-06-02
AU2020216925B2 (en) 2022-09-15
ZA202105344B (en) 2023-01-25
KR20220079688A (ko) 2022-06-13
KR102697726B1 (ko) 2024-08-21
AU2020216925A1 (en) 2021-09-02
IL285184A (en) 2021-09-30
BR112021014640A2 (pt) 2021-09-21
US20250144072A9 (en) 2025-05-08
US11426382B2 (en) 2022-08-30
CL2021001968A1 (es) 2022-01-28
ZA202107474B (en) 2022-06-29
JP2024039020A (ja) 2024-03-21
IL285184B2 (en) 2023-12-01
IL285184B1 (en) 2023-08-01
EP3917921A1 (en) 2021-12-08
US20210038568A1 (en) 2021-02-11
US11020374B2 (en) 2021-06-01
KR20210130157A (ko) 2021-10-29
US20220356319A1 (en) 2022-11-10
CO2021011042A2 (es) 2022-01-17
MX2023014776A (es) 2024-01-15
JP2025165933A (ja) 2025-11-05
CN115385871A (zh) 2022-11-25
WO2020159959A1 (en) 2020-08-06
CN112638903B (zh) 2022-08-26
CA3128152A1 (en) 2020-08-06
CN112638903A (zh) 2021-04-09
MX2021009033A (es) 2021-10-13
SG11202108160YA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
JP2024039020A (ja) サルカルディン塩
BR112020022738A2 (pt) formas cristalinas de um inibidor tlr7/tlr8
JP2023550428A (ja) インテグリン阻害剤およびその使用
JP2022503890A (ja) ２－（１－アシルオキシ－ｎ－ペンチル）安息香酸と塩基性アミノ酸またはアミノグアニジンによって形成される塩と、その製造方法及び用途
JP7825636B2 (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
JP2017193561A (ja) ３−（４−ニトロ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの固体形態
ES2651689T3 (es) Forma salina de alfa-6-mPEG6-O-hidroxicodona sólida como antagonista opioide y usos de la misma
HK40079384A (en) Sulcardine salts
HK40049638B (en) Sulcardine salts
HK40049638A (en) Sulcardine salts
BR112021002200A2 (pt) sal erbumina de trepostinila
JP2019530719A (ja) ４−（２−（（１ｒ，２ｒ）−２−ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール−６−イルオキシ）−ｎ−メチルピコリンアミドの結晶形
EA043571B1 (ru) Соли сулькардина
BR112015008931B1 (pt) Forma cristalina de (3s,3s) 4,4-disulfanodiilbis(ácido 3-aminobutano 1-sulfônico) de absd; processo para a preparação de uma forma cristalina de absd e l-lisina; e composição farmacêutica
CN105367622B (zh) 一种阿加曲班化合物
KR20250026776A (ko) 고요산혈증 또는 통풍 치료 또는 예방을 위한 화합물의 고체 결정형
WO2024169765A1 (zh) 一种二肽类化合物的盐、其制备方法和用途
BRPI0707997A2 (pt) forma cristalizada i de besipiridina.hcl, processo para sua obtenção, uso desta e composição terapêutica
EA043230B1 (ru) Эрбуминовая соль трепростинила
BR112019015487A2 (pt) Formas cristalinas de tebipenem pivoxil, composições incluindo as mesmas, métodos de fabricação e métodos de uso
PT100508B (pt) Composicoes farmaceuticas e processo para a sua preparacao
NZ759132B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221028

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221